
Structure Therapeutics
South San Francisco, California, United StatesFounded 2016188+ employeesGPCR
$1.8B raisedIPO· last: post ipo equity (Dec 2025)· 7 rounds
Backed by(21 investors)
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, Structure Therapeutics has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world.